Published in Mol Psychiatry on May 16, 2006
Dendritic spine pathology in neuropsychiatric disorders. Nat Neurosci (2011) 4.80
The neuregulin-1 receptor erbB4 controls glutamatergic synapse maturation and plasticity. Neuron (2007) 2.96
Schizophrenia is associated with an increase in cortical microRNA biogenesis. Mol Psychiatry (2009) 2.16
Schizophrenia from a neural circuitry perspective: advancing toward rational pharmacological therapies. J Clin Invest (2009) 1.87
Dendritic spine dynamics--a key role for kalirin-7. Trends Neurosci (2008) 1.55
Cell type-specific development of NMDA receptors in the interneurons of rat prefrontal cortex. Neuropsychopharmacology (2009) 1.43
Synaptic proteins in the hippocampus indicative of increased neuronal activity in CA3 in schizophrenia. Am J Psychiatry (2015) 1.40
PSD-95-like membrane associated guanylate kinases (PSD-MAGUKs) and synaptic plasticity. Curr Opin Neurobiol (2011) 1.34
Rethinking schizophrenia in the context of normal neurodevelopment. Front Cell Neurosci (2013) 1.33
Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-Methyl-D-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortex. Biol Psychiatry (2007) 1.28
Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia. Mol Psychiatry (2012) 1.27
Disruption of Arp2/3 results in asymmetric structural plasticity of dendritic spines and progressive synaptic and behavioral abnormalities. J Neurosci (2013) 1.19
Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications. Handb Exp Pharmacol (2012) 1.12
NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia. Front Cell Neurosci (2013) 1.12
Decreased expression of NMDA receptor-associated proteins in frontal cortex of elderly patients with schizophrenia. Neuroreport (2009) 1.10
Developmental regulation of the NMDA receptor subunits, NR3A and NR1, in human prefrontal cortex. Cereb Cortex (2008) 1.09
Altered vesicular glutamate transporter expression in the anterior cingulate cortex in schizophrenia. Biol Psychiatry (2007) 1.09
Reduced expression of the NMDA receptor-interacting protein SynGAP causes behavioral abnormalities that model symptoms of Schizophrenia. Neuropsychopharmacology (2009) 1.09
Prefrontal cortical dendritic spine pathology in schizophrenia and bipolar disorder. JAMA Psychiatry (2014) 1.08
Knockdown of mental disorder susceptibility genes disrupts neuronal network physiology in vitro. Mol Cell Neurosci (2011) 1.06
Abnormal activity of the MAPK- and cAMP-associated signaling pathways in frontal cortical areas in postmortem brain in schizophrenia. Neuropsychopharmacology (2011) 1.05
Elevated levels of NR2A and PSD-95 in the lateral amygdala in depression. Int J Neuropsychopharmacol (2008) 1.03
NMDA receptor subunit expression in GABAergic interneurons in the prefrontal cortex: application of laser microdissection technique. J Neurosci Methods (2008) 1.01
Expression of the NR2B-NMDA receptor trafficking complex in prefrontal cortex from a group of elderly patients with schizophrenia. Schizophr Res (2010) 1.00
Dizocilpine (MK-801) induces distinct changes of N-methyl-D-aspartic acid receptor subunits in parvalbumin-containing interneurons in young adult rat prefrontal cortex. Int J Neuropsychopharmacol (2009) 0.97
Cortical expression of glial fibrillary acidic protein and glutamine synthetase is decreased in schizophrenia. Schizophr Res (2008) 0.96
The first decade and beyond of transcriptional profiling in schizophrenia. Neurobiol Dis (2011) 0.95
High frequency of known copy number abnormalities and maternal duplication 15q11-q13 in patients with combined schizophrenia and epilepsy. BMC Med Genet (2011) 0.95
Peptide sharing between influenza A H1N1 hemagglutinin and human axon guidance proteins. Schizophr Bull (2013) 0.93
The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies. Ann N Y Acad Sci (2014) 0.92
Metabotropic glutamate receptor mGluR2/3 and mGluR5 binding in the anterior cingulate cortex in psychotic and nonpsychotic depression, bipolar disorder and schizophrenia: implications for novel mGluR-based therapeutics. J Psychiatry Neurosci (2014) 0.92
Update on the neurobiology of schizophrenia: a role for extracellular microdomains. Minerva Psichiatr (2012) 0.91
Postmortem brain: an underutilized substrate for studying severe mental illness. Neuropsychopharmacology (2013) 0.91
Dysfunctional gene splicing as a potential contributor to neuropsychiatric disorders. Am J Med Genet B Neuropsychiatr Genet (2011) 0.90
Receptor-associated proteins and synaptic plasticity. FASEB J (2008) 0.90
The kinesin superfamily protein KIF17: one protein with many functions. Biomol Concepts (2012) 0.89
Elevated GRIA1 mRNA expression in Layer II/III and V pyramidal cells of the DLPFC in schizophrenia. Schizophr Res (2007) 0.89
Common mechanisms of excitatory and inhibitory imbalance in schizophrenia and autism spectrum disorders. Curr Mol Med (2015) 0.89
Gene expression analysis implicates a death receptor pathway in schizophrenia pathology. PLoS One (2012) 0.88
N-linked glycosylation of cortical N-methyl-D-aspartate and kainate receptor subunits in schizophrenia. Neuroreport (2013) 0.86
Extensive neuroadaptive changes in cortical gene-transcript expressions of the glutamate system in response to repeated intermittent MDMA administration in adolescent rats. BMC Neurosci (2008) 0.84
Regional differences in expression of β-tubulin isoforms in schizophrenia. Schizophr Res (2012) 0.83
Homer2 deletion alters dendritic spine morphology but not alcohol-associated adaptations in GluN2B-containing N-methyl-D-aspartate receptors in the nucleus accumbens. Front Pharmacol (2015) 0.83
Evidence for shared genetic risk between methamphetamine-induced psychosis and schizophrenia. Neuropsychopharmacology (2013) 0.82
Genetic and functional analysis of the DLG4 gene encoding the post-synaptic density protein 95 in schizophrenia. PLoS One (2010) 0.82
The glutamatergic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatment. Curr Neuropharmacol (2014) 0.82
Specific Roles of NMDA Receptor Subunits in Mental Disorders. Curr Mol Med (2015) 0.80
Glutamate receptor abnormalities in schizophrenia: implications for innovative treatments. Biomol Ther (Seoul) (2012) 0.80
Mutant disrupted-in-schizophrenia 1 in astrocytes: focus on glutamate metabolism. J Neurosci Res (2014) 0.78
Discordant behavioral effects of psychotomimetic drugs in mice with altered NMDA receptor function. Psychopharmacology (Berl) (2010) 0.78
The involvement of N-methyl-d-aspartate receptor (NMDAR) subunit NR1 in the pathophysiology of schizophrenia. Acta Biochim Biophys Sin (Shanghai) (2016) 0.77
Glutamate Neurotransmission in Psychotic Disorders and Substance Abuse. Open Psychiatr J (2009) 0.77
Molecular evidence of synaptic pathology in the CA1 region in schizophrenia. NPJ Schizophr (2016) 0.77
Increased expression of retinoic acid-induced gene 1 in the dorsolateral prefrontal cortex in schizophrenia, bipolar disorder, and major depression. Neuropsychiatr Dis Treat (2015) 0.77
Altered neuronal excitability underlies impaired hippocampal function in an animal model of psychosis. Front Behav Neurosci (2015) 0.76
VCP and ATL1 regulate endoplasmic reticulum and protein synthesis for dendritic spine formation. Nat Commun (2016) 0.76
Reductions in synaptic proteins and selective alteration of prepulse inhibition in male C57BL/6 mice after postnatal administration of a VIP receptor (VIPR2) agonist. Psychopharmacology (Berl) (2015) 0.76
A Novel Bio-Psychosocial-Behavioral Treatment Model in Schizophrenia. Int J Mol Sci (2017) 0.75
Postsynaptic density levels of the NMDA receptor NR1 subunit and PSD-95 protein in prefrontal cortex from people with schizophrenia. NPJ Schizophr (2015) 0.75
Specialized roles of neurofilament proteins in synapses: Relevance to neuropsychiatric disorders. Brain Res Bull (2016) 0.75
Reciprocal Alterations in Regulator of G Protein Signaling 4 and microRNA16 in Schizophrenia. Schizophr Bull (2015) 0.75
Immunoreactivity for the NMDA NR1 subunit in bulbospinal catecholamine and serotonin neurons of rat ventral medulla. Auton Neurosci (2013) 0.75
Resequencing and Association Analysis of Six PSD-95-Related Genes as Possible Susceptibility Genes for Schizophrenia and Autism Spectrum Disorders. Sci Rep (2016) 0.75
Influence of Genetic Variants of the N-Methyl-D-Aspartate Receptor on Emotion and Social Behavior in Adolescents. Neural Plast (2015) 0.75
A cell culture model for investigation of synapse influenceability: epigenetics, expression and function of gene targets important for synapse formation and preservation in SH-SY5Y neuroblastoma cells differentiated by retinoic acid. J Neural Transm (Vienna) (2017) 0.75
Postsynaptic Density-95 Isoform Abnormalities in Schizophrenia. Schizophr Bull (2017) 0.75
Mapping the Consequences of Impaired Synaptic Plasticity in Schizophrenia through Development: An Integrative Model for Diverse Clinical Features. Trends Cogn Sci (2017) 0.75
Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci U S A (2001) 6.68
Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA (2000) 6.55
Intraneuronal Abeta42 accumulation in human brain. Am J Pathol (2000) 3.83
Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA (1999) 3.22
Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am J Psychiatry (1998) 1.95
Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia. Am J Psychiatry (2000) 1.93
Coronary artery disease is associated with Alzheimer disease neuropathology in APOE4 carriers. Neurology (2006) 1.89
Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons. Neurology (2009) 1.78
Dissociation of neuropathology from severity of dementia in late-onset Alzheimer disease. Neurology (2006) 1.68
Neuropeptide abnormalities in patients with early Alzheimer disease. Arch Gen Psychiatry (1999) 1.62
Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood (1995) 1.59
Localization of dopamine D2 receptor mRNA and D1 and D2 receptor binding in the rat brain and pituitary: an in situ hybridization-receptor autoradiographic analysis. J Neurosci (1990) 1.56
Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex. Biol Psychiatry (1996) 1.52
A common ancestral origin of the frequent and widespread 2299delG USH2A mutation. Am J Hum Genet (2001) 1.49
Positive and negative symptoms in schizophrenia and the Dexamethasone Suppression Test. Biol Psychiatry (1989) 1.42
Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J Neurochem (1995) 1.41
Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology. Neurology (2008) 1.41
Alzheimer disease and related neurodegenerative diseases in elderly patients with schizophrenia: a postmortem neuropathologic study of 100 cases. Arch Gen Psychiatry (1998) 1.39
Elevated cortical zinc in Alzheimer disease. Neurology (2006) 1.38
Mitochondrial damage in Alzheimer's disease varies with apolipoprotein E genotype. Ann Neurol (2000) 1.35
Identification of 14 novel mutations in the long isoform of USH2A in Spanish patients with Usher syndrome type II. J Med Genet (2006) 1.27
Variations in differential gene expression patterns across multiple brain regions in schizophrenia. Schizophr Res (2005) 1.24
Postmortem studies in schizophrenia. Schizophr Bull (1998) 1.23
Increased serotonin 2C receptor mRNA editing: a possible risk factor for suicide. Mol Psychiatry (2007) 1.22
Emergence of interoceptive and exteroceptive control of behavior in rats. Science (1979) 1.17
Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease. Arch Neurol (2001) 1.17
Novel (60%) and recurrent (40%) androgen receptor gene mutations in a series of 59 patients with a 46,XY disorder of sex development. J Clin Endocrinol Metab (2010) 1.16
Correlation between Abetax-40-, Abetax-42-, and Abetax-43-containing amyloid plaques and cognitive decline. Arch Neurol (2001) 1.15
Elevated serum total and LDL cholesterol in very old patients with Alzheimer's disease. Dement Geriatr Cogn Disord (2001) 1.15
Expression of excitatory amino acid transporter transcripts in the thalamus of subjects with schizophrenia. Am J Psychiatry (2001) 1.14
Dopamine receptor mRNA expression in human striatum and neocortex. Neuropsychopharmacology (1996) 1.13
A comparison of D1 receptor binding and mRNA in rat brain using receptor autoradiographic and in situ hybridization techniques. Neuroscience (1992) 1.11
DNA microarray analysis of functionally discrete human brain regions reveals divergent transcriptional profiles. Neurobiol Dis (2003) 1.10
The validity of the family history method for identifying Alzheimer disease. Arch Neurol (1997) 1.09
Differential proliferative responses of cultured Schwann cells to axolemma and myelin-enriched fractions. II. Morphological studies. J Neurocytol (1985) 1.09
N-methyl-D-aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia. Am J Psychiatry (2001) 1.08
Site-directed mutagenesis of the human dopamine D2 receptor. Eur J Pharmacol (1992) 1.08
The tyrosine phosphatase STEP: implications in schizophrenia and the molecular mechanism underlying antipsychotic medications. Transl Psychiatry (2012) 1.08
Differential prevalence of cigarette smoking in patients with schizophrenic vs mood disorders. Schizophr Res (1998) 1.07
Mutation profile of the MYO7A gene in Spanish patients with Usher syndrome type I. Hum Mutat (2006) 1.07
Nicotine withdrawal and psychiatric symptoms in cigarette smokers with schizophrenia. Neuropsychopharmacology (1999) 1.06
Differential brain expression of the Alzheimer's amyloid precursor protein. EMBO J (1989) 1.06
MYO7A mutation screening in Usher syndrome type I patients from diverse origins. J Med Genet (2007) 1.05
Dopamine receptor transcript expression in striatum and prefrontal and occipital cortex. Focal abnormalities in orbitofrontal cortex in schizophrenia. Arch Gen Psychiatry (1997) 1.04
Epidemiology of Usher syndrome in Valencia and Spain. Community Genet (1998) 1.04
Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia. Arch Neurol (2000) 1.03
Selective loss of dopamine D3-type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia. Proc Natl Acad Sci U S A (1993) 1.03
An autosomal dominant retinitis pigmentosa family with close linkage to D7S480 on 7q. Hum Genet (1995) 1.02
Evidence against involvement of recoverin in autosomal recessive retinitis pigmentosa in 42 Spanish families. Hum Genet (1995) 1.02
Increased synthesis and accumulation of heat shock 70 proteins in Alzheimer's disease. Brain Res Mol Brain Res (1991) 1.02
Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. Neuroreport (1994) 1.01
Levels of mRNAs encoding synaptic vesicle and synaptic plasma membrane proteins in the temporal cortex of elderly schizophrenic patients. Biol Psychiatry (2000) 1.01
Expression of the NR2B-NMDA receptor trafficking complex in prefrontal cortex from a group of elderly patients with schizophrenia. Schizophr Res (2010) 1.00
Dysregulation of dynorphins in Alzheimer disease. Neurobiol Aging (2006) 0.98
Vesicular glutamate transporter transcript expression in the thalamus in schizophrenia. Neuroreport (2001) 0.98
Altered expression of a-type but not b-type synapsin isoform in the brain of patients at high risk for Alzheimer's disease assessed by DNA microarray technique. Neurosci Lett (2001) 0.98
Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases. Eur J Pharmacol (2000) 0.96
A comparison of D1 receptor binding and mRNA in rat brain using receptor autoradiographic and in situ hybridization techniques. Neuroscience (1991) 0.95
Mutations in the human peripherin/RDS gene associated with autosomal dominant retinitis pigmentosa. Hum Mutat (1994) 0.95
CNS oxidative stress associated with the kainic acid rodent model of experimental epilepsy. Epilepsy Res (2000) 0.94
Increased concentrations of presynaptic proteins in the cingulate cortex of subjects with schizophrenia. Arch Gen Psychiatry (1997) 0.93
Smoking, smoking withdrawal and schizophrenia: case reports and a review of the literature. Schizophr Res (1996) 0.92
Mutation analysis of the RPGR gene reveals novel mutations in south European patients with X-linked retinitis pigmentosa. Eur J Hum Genet (1999) 0.91
Metabotropic glutamate receptor mRNA expression in the schizophrenic thalamus. Biol Psychiatry (2000) 0.90
Quantitative analysis of glutamate transporter mRNA expression in prefrontal and primary visual cortex in normal and schizophrenic brain. Neuroscience (2005) 0.90
Dexamethasone suppression test in schizophrenia: relationship to symptomatology, ventricular enlargement, and outcome. Biol Psychiatry (1991) 0.90
Linkage analysis in Usher syndrome type I (USH1) families from Spain. J Med Genet (1998) 0.89
Ontogeny of ionotropic glutamate receptor expression in human fetal brain. Brain Res Dev Brain Res (2001) 0.88
On the distribution patterns of D1, D2, tyrosine hydroxylase and dopamine transporter immunoreactivities in the ventral striatum of the rat. Neuroscience (1999) 0.88
Increased biosynthesis of Alzheimer amyloid precursor protein in the cerebral cortex of rats with lesions of the nucleus basalis of Meynert. Brain Res Mol Brain Res (1991) 0.88
Acute feasibility and safety of a smoking reduction strategy for smokers with schizophrenia. Nicotine Tob Res (1999) 0.88
Amyloid precursor protein in the cerebral cortex is rapidly and persistently induced by loss of subcortical innervation. Proc Natl Acad Sci U S A (1993) 0.87
Insights into the role of microRNAs in cardiac diseases: from biological signalling to therapeutic targets. Cardiovasc Hematol Agents Med Chem (2009) 0.87
Differential proliferative responses of cultured Schwann cells to axolemma- and myelin-enriched fractions. I. Biochemical studies. J Cell Biol (1984) 0.86
Cholesterol and LDL relate to neuritic plaques and to APOE4 presence but not to neurofibrillary tangles. Curr Alzheimer Res (2011) 0.86
Cyclic AMP and calcium as potential mediators of stimulation of cultured Schwann cell proliferation by axolemma-enriched and myelin-enriched membrane fractions. Biochem Biophys Res Commun (1984) 0.86
The human dopamine D5 receptor gene: cloning and characterization of the 5'-flanking and promoter region. Biochemistry (1995) 0.86
Apolipoprotein E-epsilon 4 allele and familial risk in Alzheimer's disease. Genet Epidemiol (1996) 0.86
Abnormal kainate receptor expression in prefrontal cortex in schizophrenia. Neuropsychopharmacology (2001) 0.85
AMPA receptor binding and subunit mRNA expression in prefrontal cortex and striatum of elderly schizophrenics. Neuropsychopharmacology (1998) 0.85
Mutation screening of USH3 gene (clarin-1) in Spanish patients with Usher syndrome: low prevalence and phenotypic variability. Clin Genet (2004) 0.85
Linking the family of D2 receptors to neuronal circuits in human brain: insights into schizophrenia. Neuropsychopharmacology (1997) 0.84
The role of life events in onset and recurrent episodes of schizophrenia and schizoaffective disorder. J Psychiatr Res (1999) 0.84
Perceptual sharpening in the developing rat. J Comp Psychol (1983) 0.83
Gene expression signature is shared by patients with Alzheimer's disease and schizophrenia at the superior temporal gyrus. Eur J Neurol (2011) 0.83
Effect of arousal conditions during reinstatement treatment upon learned fear in young rats. Dev Psychobiol (1977) 0.83
Epidemiology of retinitis pigmentosa in the Valencian community (Spain). Genet Epidemiol (1995) 0.83
Clinical, cognitive and functional characteristics of long-stay patients with schizophrenia: a comparison of VA and state hospital patients. Schizophr Res (2000) 0.83
Correlation of the clinical severity of Alzheimer's disease with an aberration in mitochondrial DNA (mtDNA). J Mol Neurosci (2001) 0.82
Paradoxical locomotor behavior of dopamine D1 receptor transgenic mice. Exp Neurol (1999) 0.82
Alterations in cerebral cortical galanin concentrations following neurotransmitter-specific subcortical lesions in the rat. J Neurosci (1995) 0.82
Inositol levels are decreased in postmortem brain of schizophrenic patients. Biol Psychiatry (1998) 0.82
Lack of dopamine receptor agonists effect on striatal dopamine transporter binding sites. Brain Res (1996) 0.82
SRD5A2 gene mutations and polymorphisms in Spanish 46,XY patients with a disorder of sex differentiation. Int J Androl (2011) 0.82